Patterns of subretinal fluid resolution in Group D eyes treated with chemoreduction: Experience from the Children’s Hospital Los Angeles/University of Southern California

ABSTRACT

The purpose of this study was to evaluate patterns of subretinal fluid (SRF) resolution in Group D retinoblastoma eyes. Fifty-three Group D eyes were evaluated for the presence of SRF at diagnosis. They were subsequently treated with systemic chemoreduction (CRD) and the duration of SRF was evaluated. Logistic regression analysis was used to assess the association between duration of SRF and enucleation. Among the 53 Group D eyes, 42 eyes exhibited SRF at diagnosis (79%). After the first cycle of CRD, 27/42 eyes showed SRF (64%); 8/42 eyes demonstrated SRF after three cycles of CRD (19%), and only 3/42 eyes had SRF after six cycles (7%). Ten eyes were enucleated (10/53 or 19%). Only 1 of 10 eyes demonstrated persistent SRF at the time of enucleation. This retrospective analysis of patterns of subretinal fluid in retinoblastoma eyes demonstrates that 80% of Group D eyes present with SRF. Of these eyes, approximately 60% have persistent fluid after one cycle of CRD and less than 10% have persistent fluid after six cycles. However, presence or persistence of SRF during chemoreduction was not found to be a risk factor for enucleation in Group D retinoblastoma eyes.

KEYWORDS:

• Chemoreduction
• chemotherapy
• retinal detachment
• retinoblastoma
• subretinal fluid

Acknowledgements

We would like to thank Choo Phei Wee, MS for her statistical expertise on this project.

This study was presented at the following conferences: Association of Research in Vision and Ophthalmology, Denver, CO, USA, May 2015, and International Society of Ocular Oncology, Paris, France, June 2015.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding

This work was supported by an unrestricted departmental grant from Research to Prevent Blindness, The Institute for Families, Inc., and Retinoblastoma International, Inc.

Additional information

Funding

This work was supported by an unrestricted departmental grant from Research to Prevent Blindness, The Institute for Families, Inc., and Retinoblastoma International, Inc.